Conference Dates: August 10-14, 2003
Conference Location: Vancouver, British Columbia, Canada
Sponsoring Group: International Association for the Study of Lung Cancer
Conference Web Page URL: www.2003worldlungcancer.org
Topics Covered: Review of eepidemiology of the global lung cancer problem Update on the monecular biology of lung cancer CME by foremost lung cancer authorities Leading edge research on lung cancer management
Conference Objectives: Th conference will highlight important advances in lung cancer in the aeras of prevention, early detection, molecular biology, biothecnology and therapy.
Who Should Attend: Surgeons, oncologists, radiation therapists,pulmonologists, radiologists, pathologists
Conference Agenda: Reconize the importance of tobacco smoking inthe global lung cancer epidemic Re-evaluate the role of lung cancer screening Identify the latest improvements in lung cancer diagnosis Reconize current standards of treatment for lung cancer Identify new molecular targets for lung cancer therapy
Registration Information: Visit the conference website for registration information, in October 2003
Conference Fees: IASLC members: $630 USD. Non-members: $730 USD. RN's and developing Nations: $300 USD
Continuing Education: Yes
Miscellany: Abstracts deadline is February 15, 2003
Jul 7, 2011 - Erlotinib is superior to chemotherapy for improving progression free survival in patients with non-small-cell lung cancer and epidermal growth factor receptor mutations, with acceptable toxicity, according to a study presented at the 14th World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer and held from July 3 to 7 in Amsterdam, Netherlands.
Jul 7, 2011
Jan 12, 2012
Nov 4, 2010